Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 1 min ago
Peer-reviewedCC BY 4.0Frontiers in Cardiovascular Medicine

Early outcomes of microaxial flow pump (Impella)–supported coronary artery bypass grafting for acute myocardial infarction with cardiogenic shock: national reference estimates from the J-PVAD registry

  • Yoshinori Nakahara1
  • Tomohiro Iwakura1
  • Akira Marui1
  • Yuito Okada1
  1. 1Department of Cardiovascular Surgery, Sakakibara Heart Institute
Open at sourceDOICite

Abstract

Background: Contemporary national data on outcomes of coronary artery bypass grafting (CABG) performed under microaxial flow pump (Impella) support for acute myocardial infarction (AMI) complicated by cardiogenic shock are scarce. We aimed to provide contemporary national reference estimates and, as a post hoc exploratory analysis, to describe outcomes according to the setting of Impella insertion.

Methods: From the Japanese Registry for Percutaneous Ventricular Assist Devices (J-PVAD; February 2020 to December 2024), we analyzed 245 patients from 116 centers with AMI-related cardiogenic shock who underwent CABG under Impella support, after excluding ventricular septal perforation repair and unsuccessful insertion. The primary outcome was all-cause mortality within 30 days after Impella implantation; in-hospital mortality and adverse events were secondary. Proportions are reported with Wilson 95% confidence intervals (CIs). Operating-room insertion ( n = 19) was compared with non-operating-room insertion ( n = 226) by Firth-penalized logistic regression with propensity score overlap weighting (age, systolic blood pressure, and extracorporeal membrane oxygenation initiated before Impella).

Results: Thirty-day mortality was 20.8% (51/245; 95% CI: 16.2–26.3); in 24 patients discharged alive before day 30, survival to day 30 was assumed from the recorded status. In-hospital mortality was 33.1% (81/245; 95% CI: 27.5–39.2). Adverse events included bleeding (17.6%; 95% CI: 13.3–22.8), renal failure (9.8%), sepsis (9.0%), hemolysis (8.6%), and stroke (6.5%). Thirty-day mortality was 36.8% (7/19) after operating-room insertion and 19.5% (44/226) after non-operating-room insertion (weighted odds ratio 1.63; 95% CI: 0.62–4.16). This estimate had a wide confidence interval, consistent with either a substantially lower or a substantially higher mortality after operating-room insertion, and more than half of the baseline characteristics remained imbalanced after weighting.

Conclusion: These nationwide data provide contemporary reference estimates for Impella-supported CABG in AMI-related cardiogenic shock. The registry records the setting (operating room or elsewhere), but not the intent or clinical timing, of Impella insertion, and the comparative safety of operating-room vs. non-operating-room insertion cannot be determined from these data.

Related

  1. Acute Anterior ST-Elevation Myocardial Infarction With Right Bundle Branch Block Complicated by Complete Atrioventricular Block and Cardiogenic Shock in a 21-Year-Old Man: A Case Report
    Nicholas Wijaya, Hanif A Sulistya, Yusuf Arifin +2
    CureusPeer-reviewedCC BYFull textCardiovascular medicineEurope PMCPMCEurope PMC
  2. From cardiogenic shock to surgical success: Addressing ventricular septal rupture in a myocardial infarction case
    Akif Ahamad Baig, Mohammed Abdul Sameena Farheen, Sudheer Mojjada
    Journal of Dr. NTR University of Health SciencesPeer-reviewedCC BY-NC-SAFull textSurgery & anaesthesiaDOAJ
  3. Timing of Microaxial Flow Pump Support and In-Hospital Mortality in Infarct-Related Cardiogenic Shock: The TIMING-CS Study
    Klevis Mihali, Julian Kreutz, Birgit Markus +7
    Journal of cardiovascular development and diseasePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  4. Mortality risk stratification in contemporary myocardial infarction-related cardiogenic shock: development of AMICS-ADMIT prediction model and benchmarking of established scores.
    Klevis Mihali, Birgit Markus, Kornelia Neuner +7
    International journal of cardiology. Heart & vasculaturePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  5. National Use Patterns and Comparative Effectiveness of Extracorporeal Membrane Oxygenation in Myocardial Infarction–Related Cardiogenic Shock
    Ajar Kochar, Christina Lalani, Yang Song +9
    Journal of the American Heart AssociationPeer-reviewedCC BYFull textCardiovascular medicineCrossrefDOAJ

Cite

BibTeXRIS
BibTeX
@article{nakahara2026early,
  title = {{Early outcomes of microaxial flow pump (Impella)–supported coronary artery bypass grafting for acute myocardial infarction with cardiogenic shock: national reference estimates from the J-PVAD registry}},
  author = {Yoshinori Nakahara and Tomohiro Iwakura and Akira Marui and Yuito Okada},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  month = nov,
  doi = {10.3389/fcvm.2026.1941963},
  url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1941963/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Early outcomes of microaxial flow pump (Impella)–supported coronary artery bypass grafting for acute myocardial infarction with cardiogenic shock: national reference estimates from the J-PVAD registry
AU  - Yoshinori Nakahara
AU  - Tomohiro Iwakura
AU  - Akira Marui
AU  - Yuito Okada
PY  - 2026
DA  - 2026/11/02
JO  - Frontiers in Cardiovascular Medicine
DO  - 10.3389/fcvm.2026.1941963
UR  - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1941963/full
AB  - Background: Contemporary national data on outcomes of coronary artery bypass grafting (CABG) performed under microaxial flow pump (Impella) support for acute myocardial infarction (AMI) complicated by cardiogenic shock are scarce. We aimed to provide contemporary national reference estimates and, as a post hoc exploratory analysis, to describe outcomes according to the setting of Impella insertion.  Methods: From the Japanese Registry for Percutaneous Ventricular Assist Devices (J-PVAD; February 2020 to December 2024), we analyzed 245 patients from 116 centers with AMI-related cardiogenic shock who underwent CABG under Impella support, after excluding ventricular septal perforation repair and unsuccessful insertion. The primary outcome was all-cause mortality within 30 days after Impella implantation; in-hospital mortality and adverse events were secondary. Proportions are reported with Wilson 95% confidence intervals (CIs). Operating-room insertion ( n = 19) was compared with non-operating-room insertion ( n = 226) by Firth-penalized logistic regression with propensity score overlap weighting (age, systolic blood pressure, and extracorporeal membrane oxygenation initiated before Impella).  Results: Thirty-day mortality was 20.8% (51/245; 95% CI: 16.2–26.3); in 24 patients discharged alive before day 30, survival to day 30 was assumed from the recorded status. In-hospital mortality was 33.1% (81/245; 95% CI: 27.5–39.2). Adverse events included bleeding (17.6%; 95% CI: 13.3–22.8), renal failure (9.8%), sepsis (9.0%), hemolysis (8.6%), and stroke (6.5%). Thirty-day mortality was 36.8% (7/19) after operating-room insertion and 19.5% (44/226) after non-operating-room insertion (weighted odds ratio 1.63; 95% CI: 0.62–4.16). This estimate had a wide confidence interval, consistent with either a substantially lower or a substantially higher mortality after operating-room insertion, and more than half of the baseline characteristics remained imbalanced after weighting.  Conclusion: These nationwide data provide contemporary reference estimates for Impella-supported CABG in AMI-related cardiogenic shock. The registry records the setting (operating room or elsewhere), but not the intent or clinical timing, of Impella insertion, and the comparative safety of operating-room vs. non-operating-room insertion cannot be determined from these data.
SN  - 2297-055X
ER  -